DK2116255T3 - Intratekal indgivelse af hgf efter rygmarvsskade - Google Patents

Intratekal indgivelse af hgf efter rygmarvsskade

Info

Publication number
DK2116255T3
DK2116255T3 DK08721006.8T DK08721006T DK2116255T3 DK 2116255 T3 DK2116255 T3 DK 2116255T3 DK 08721006 T DK08721006 T DK 08721006T DK 2116255 T3 DK2116255 T3 DK 2116255T3
Authority
DK
Denmark
Prior art keywords
hgf
spinal cord
cord injury
intrathecal administration
following spinal
Prior art date
Application number
DK08721006.8T
Other languages
English (en)
Inventor
Hideyuki Okano
Yoshiaki Toyama
Masaya Nakamura
Akio Iwanami
Kazuya Kitamura
Toshikazu Nakamura
Hiroshi Funakoshi
Keigo Hanada
Original Assignee
Univ Keio
Univ Osaka
Kringle Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Keio, Univ Osaka, Kringle Pharma Inc filed Critical Univ Keio
Application granted granted Critical
Publication of DK2116255T3 publication Critical patent/DK2116255T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08721006.8T 2007-02-28 2008-02-28 Intratekal indgivelse af hgf efter rygmarvsskade DK2116255T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2007/053804 WO2008105088A1 (ja) 2007-02-28 2007-02-28 脊髄損傷治療薬剤
PCT/JP2008/053557 WO2008105507A1 (ja) 2007-02-28 2008-02-28 脊髄損傷治療薬剤

Publications (1)

Publication Number Publication Date
DK2116255T3 true DK2116255T3 (da) 2013-05-13

Family

ID=39720932

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08721006.8T DK2116255T3 (da) 2007-02-28 2008-02-28 Intratekal indgivelse af hgf efter rygmarvsskade

Country Status (10)

Country Link
US (1) US8518880B2 (da)
EP (1) EP2116255B1 (da)
KR (2) KR101670677B1 (da)
CN (2) CN105311620A (da)
CA (1) CA2675953C (da)
DK (1) DK2116255T3 (da)
ES (1) ES2412388T3 (da)
HK (1) HK1134445A1 (da)
PT (1) PT2116255E (da)
WO (2) WO2008105088A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010041716A1 (ja) * 2008-10-10 2010-04-15 クリングルファーマ株式会社 腱骨移行部組織または靭帯骨移行部組織の再生促進剤
CN103140226B (zh) 2010-08-06 2015-07-08 大日本住友制药株式会社 用于治疗脊髓损伤的制剂
KR101446711B1 (ko) * 2011-05-23 2014-10-06 아주대학교산학협력단 간세포 성장인자 유전자 및 염기성 나선-고리-나선 계열의 신경형성 전사인자 유전자가 도입된 성체 줄기세포주 및 그의 용도
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤
US10716564B2 (en) 2017-02-17 2020-07-21 Ethicon Llc Stapling adjunct attachment
US10478280B2 (en) * 2017-02-17 2019-11-19 Ethicon Llc Methods and devices for delivering and securing adjunct materials to a treatment site
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
CN113433324B (zh) * 2021-05-28 2022-11-18 南通大学 Nck1蛋白作为标志物在诊断脊髓损伤中的应用
WO2023171808A1 (ja) * 2022-03-11 2023-09-14 慶應義塾 脊髄損傷治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JPH05111382A (ja) 1991-10-22 1993-05-07 Saito Signal Kenkyusho:Kk ヒト好酸球細胞株
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US7033608B1 (en) * 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
JP4441263B2 (ja) * 2001-11-28 2010-03-31 アンジェスＭｇ株式会社 神経変性疾患遺伝子治療剤
WO2004021992A2 (en) * 2002-09-06 2004-03-18 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
CN1250287C (zh) * 2002-11-20 2006-04-12 中国人民解放军军事医学科学院放射医学研究所 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用
JP2005035945A (ja) * 2003-07-16 2005-02-10 Cardio Corp 組織再生複合療法
EP1747277B1 (en) 2004-04-14 2011-08-10 Agency for Science, Technology and Research Gene delivery to neuronal cells
CN101102788A (zh) 2005-01-24 2008-01-09 克霖固鲁制药股份有限公司 移植器官纤维化抑制剂
JP2007077125A (ja) * 2005-09-16 2007-03-29 Keio Gijuku 脊髄損傷治療剤
JP2007238487A (ja) 2006-03-07 2007-09-20 Osaka Univ 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法

Also Published As

Publication number Publication date
HK1134445A1 (en) 2010-04-30
CN101610783B (zh) 2016-11-16
US20120021040A9 (en) 2012-01-26
ES2412388T3 (es) 2013-07-11
CN101610783A (zh) 2009-12-23
WO2008105088A1 (ja) 2008-09-04
EP2116255A1 (en) 2009-11-11
PT2116255E (pt) 2013-06-21
WO2008105507A1 (ja) 2008-09-04
CA2675953A1 (en) 2008-09-04
US8518880B2 (en) 2013-08-27
KR20090118078A (ko) 2009-11-17
KR20150138413A (ko) 2015-12-09
US20100081617A1 (en) 2010-04-01
CN105311620A (zh) 2016-02-10
KR101670677B1 (ko) 2016-11-01
EP2116255A4 (en) 2011-05-04
CA2675953C (en) 2016-05-10
EP2116255B1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
DK2116255T3 (da) Intratekal indgivelse af hgf efter rygmarvsskade
DK2230943T3 (da) Pædiatrisk fiberblanding
SE0702657L (sv) Hantel
DK2211901T3 (da) Vaccination med multiple clader af h5-influenza-a-virus
BRPI1011813A2 (pt) "inalador"
IT1399597B1 (it) "shaker monouso"
DK2222272T3 (da) Behandling af luftvejssygdom
DK2593463T3 (da) Formuleringer af rifaximin og anvendelser deraf
DK2114993T3 (da) Vaccine
BRPI0917205A2 (pt) vacina polivalente
DE102007041169B8 (de) Flugkorbball
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
DK2648696T3 (da) Ny indgivelsesform af racecadotril
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
FR2965705B1 (fr) Compositions d'edulcorants
BRPI0912963A2 (pt) equipamento para transfusão
DK2118174T3 (da) Anvendelse af tocopherol
DE602008005536D1 (de) Herstellung von MnB12H12
DK2121138T3 (da) Terapeutiske anvendelser af eslicarbazepin
DK2145547T3 (da) Forbedret stabilitet af aromatiske forbindelser
DK2042015T3 (da) Centrifugalspreder
ES1076579Y (es) Cuna infantil
IT1402307B1 (it) Componente d'arredo
FI20070240A0 (fi) Teleskooppinen kulkusilta